Study highlights proteins involved in tumour growth and metastasis

Image
ANI
Last Updated : Oct 24 2019 | 6:35 PM IST

Researchers from the Stowers Institute for Medical Research have found a new study about proteins involved in tumour growth and metastasis.

The study was published in the journal, 'Science Advances.'

The researchers also uncovered potential avenues for the development of treatments for diseases such as breast cancer.

The study focuses on the tumor-suppressing function of SMAD4, a transcription factor protein normally involved in the regulation of cell growth processes.

Its function is often turned off in breast cancer, which allows tumour to flourish and metastasize.

In this report, the researchers found that BRK, a non-receptor protein tyrosine kinase, binds to and leads to SMAD4 breakdown. In order to understand the research well, the study was done using human cell lines, including a panel of breast cancer cell lines.

The research suggests that treatments targeting BRK, which is present in more than 85 per cent of breast cancer tumours, may help retain SMAD4 function, therefore reducing or stopping tumour growth.

Sayem Miah, lead researchers of the study said, "The BRK kinase is present in more than 85 per cent of breast cancer tumours."

"Our research suggests that treatments targeting BRK may help keep SMAD4 function intact, therefore reducing or stopping tumour growth," added Miah.

"We've known for a while that BRK functions like an oncogene - a gene that has the potential to cause cancer when mutated or abnormally expressed - in breast cancer," he explained.

Adding, "Ultimately, we want to know whether BRK alone can drive breast cancer progression, and if so, by what mechanism."

The lead researchers believe that these findings are a vital step in understanding how cancer works and would like to find other molecules that work with BRK to degrade SMAD4. "If we can further increase our understanding of this protein network, these insights may reveal new targets for metastatic cancer intervention," he said.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Oct 24 2019 | 6:28 PM IST

Next Story